ArticleScientific reports2015
A novel 96well-formatted micro-gap plate enabling drug response profiling on primary tumour samples.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Open and closed microfluidics for biosensing.Materials today. Bio · 2024Review
- Drug screening on digital microfluidics for cancer precision medicine.Nature communications · 2024Article
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- Microcrater-Arrayed Chemiluminescence Cell Chip to Boost Anti-Cancer Drug Administration in Zebrafish Tumor Xenograft Model.Biology · 2021Article
- Fabrication approaches for high-throughput and biomimetic disease modeling.Acta biomaterialia · 2021Review
- Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response.Communications biology · 2021Article
- Specificity of 3D MSC Spheroids Microenvironment: Impact on MSC Behavior and Properties.Stem cell reviews and reports · 2020Review
- Applicability of drug response metrics for cancer studies using biomaterials.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Article
- Application of microfluidic chip technology in pharmaceutical analysis: A review.Journal of pharmaceutical analysis · 2019Article
- A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments.Scientific reports · 2019Article
- A microfluidics platform for combinatorial drug screening on cancer biopsies.Nature communications · 2018Article
- Automated fluid delivery from multiwell plates to microfluidic devices for high-throughput experiments and microscopy.Scientific reports · 2018Article
- Three-DimensionalFrontiers in pharmacology · 2018Review
- Three-dimensional spheroid culture targeting versatile tissue bioassays using a PDMS-based hanging drop array.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-based treatments are the most widely used interventions for cancer management. Personalized drug response profiling remains inherently challenging with low cell count harvested from tumour sample. We present a 96well-formatted microfluidic plate with built-in micro-gap that preserves up to 99.2% of cells during multiple assay/wash operation and only 9,000 cells needed for a single reagent test (i.e. 1,000 cells per test spot x 3 selected concentration x triplication), enabling drug screening and compatibility with conventional automated workstations. Results with MCF7 and MDA-MB-231 cell lines showed that no statistical significance was found in dose-response between the device and conventional 96-well plate control. Primary tumour samples from breast cancer patients tested in the device also showed good IC50 prediction. With drug screening of primary cancer cells must consider a wide range of scenarios, e.g. suspended/attached cell types and rare/abundant cell availability, the device enables high throughput screening even for suspended cells with low cell count since the signature microfluidic cell-trapping feature ensures cell preservation in a multiple solution exchange protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.